Kymera Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2019 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kymera Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to 2024.
  • Kymera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $13.8M, a 26.6% increase year-over-year.
  • Kymera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $55M, a 27.6% increase year-over-year.
  • Kymera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $55M, a 27.6% increase from 2023.
  • Kymera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $43.1M, a 21.5% increase from 2022.
  • Kymera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $35.5M, a 42.1% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $55M +$11.9M +27.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $43.1M +$7.64M +21.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $35.5M +$10.5M +42.1% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $25M +$19.8M +381% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $5.19M +$3.99M +334% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $1.2M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.